Clearmind Medicine Reports Positive Phase I/IIa Trial Results
Ticker: CMND · Form: 6-K · Filed: Nov 18, 2025 · CIK: 1892500
Sentiment: bullish
Topics: clinical-trial, pharmaceutical, FDA
TL;DR
Clearmind's alcohol disorder drug shows promise in early FDA trial.
AI Summary
Clearmind Medicine Inc. announced on November 18, 2025, positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder. The trial is investigating the efficacy and safety of their treatment for this condition.
Why It Matters
Positive trial results could pave the way for a new treatment option for Alcohol Use Disorder, a significant public health issue.
Risk Assessment
Risk Level: medium — Clinical trial results, especially early-stage ones, carry inherent uncertainty and are subject to further validation.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- November 18, 2025 (date) — Announcement date
- FDA (company) — Regulatory approval
- Phase I/IIa (clinical_trial_phase) — Trial stage
- Alcohol Use Disorder (medical_condition) — Condition being treated
FAQ
What specific positive top-line results were announced from the Phase I/IIa clinical trial?
The filing states positive top-line results were announced, but does not specify the exact metrics or data points in this Form 6-K.
What is the primary indication for Clearmind Medicine's clinical trial?
The primary indication is Alcohol Use Disorder.
Has the trial received approval from the FDA?
Yes, the press release incorporated by reference states it is an FDA-approved Phase I/IIa clinical trial.
When was this Form 6-K filed?
This Form 6-K was filed on November 18, 2025.
What is Clearmind Medicine Inc.'s principal executive office address?
The principal executive offices are located at 101 – 1220 West 6th Avenue, Vancouver, British Columbia.
Filing Stats: 286 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2025-11-18 16:16:22
Filing Documents
- ea0266184-6k_clearmind.htm (6-K) — 18KB
- ea026618401ex99-1_clearmind.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-112114.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: November 18, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3